Migraine Management, Volume 199 covers the effective treatment of migraines, including different subtypes of migraines in different patient populations. The classification and diagnostic criteria of common and uncommon subtypes of migraine is explored in detail, including childhood variants. An in-depth analysis of the pharmacology of acute and prophylactic agents is presented, along with an evidence-based review of pharmacologic management. This includes recently developed CGRP monoclonal antibodies and non-peptide small molecule CGRP antagonists. Advances in neuromodulatory treatments, both noninvasive and implantable, are also critically reviewed.
Finally, specific treatment-related issues in pregnancy and lactation and childhood as well as the elderly are covered. Issues related to the diagnosis and management of vestibular migraine and the co-morbid disorder of persistent postural-perceptual dizziness is also explored.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Series Page - p. iii 5. Copyright - p. iii 6. Handbook of Clinical Neurology 3rd Series - p. iii 7. Foreword - p. ix 8. Preface - p. x 9. Contributors - p. x 10. Section I: Migraine management - p. x 11. Chapter 1: Nonspecific analgesics, combination analgesics, and antiemetics - p. 3 12. Chapter 2: The 5-HT1B and 5-HT1D agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans - p. 17 13. Chapter 3: 5-HT1F agonists - p. 43 14. Chapter 4: CGRP receptor antagonists (gepants) - p. 51 15. Chapter 5: Preventive treatment of migraine: Non-specific oral agents - p. 80 16. Chapter 6: OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment - p. 87 17. Chapter 7: CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention - p. 107 18. Chapter 8: Nutraceuticals in migraine - p. 125 19. Chapter 9: Interventional treatments - p. 145 20. Chapter 10: Biobehavioral treatments of migraine - p. 155 21. Chapter 11: Physical treatment of migraine - p. 171 22. Chapter 12: Neuromodulation in migraine - p. 179 23. Section II: Guidelines - p. 200 24. Chapter 13: Evidence-based symptomatic treatment of migraine - p. 203 25. Chapter 14: Evidence-based preventive treatment of migraine☆ - p. 219 26. Section III: Special cases/situations - p. 241 27. Chapter 15: Treatment in the emergency department - p. 245 28. Chapter 16: Special considerations in migraine during pregnancy and lactation - p. 257 29. Chapter 17: Special considerations in management of migraine in the elderly - p. 265 30. Chapter 18: Management of medication overuse headache - p. 277 31. Section IV: Outcome measures - p. 298 32. Chapter 19: Outcome measures for migraine: Measuring the impact of migraine and results of migraine treatment - p. 316 33. Section V: Diagnosis and treatment of other migraine subtypes - p. 328 34. Chapter 20: Menstrually associated migraine - p. 331 35. Chapter 21: Hemiplegic migraine - p. 353 36. Chapter 22: Migraine with brainstem aura - p. 367 37. Chapter 23: Retinal migraine - p. 381 38. Chapter 24: Vestibular migraine and persistent postural perceptual dizziness - p. 389 39. Chapter 25: Status migrainosus - p. 422 40. Chapter 26: Persistent aura, visual snow, and other visual symptoms - p. 441 41. Chapter 27: Migrainous infarction - p. 465 42. Chapter 28: Migraine in children and adolescents: Assessment and diagnosis - p. 475 43. Chapter 29: Management of migraine in children and adolescents - p. 487 44. Section VI: Comorbidities of migraine - p. 502 45. Chapter 30: Psychiatric comorbidities of migraine - p. 505 46. Chapter 31: Relationship of migraine and other forms of chronic pain - p. 517 47. Chapter 32: Comorbidities of migraine: Sleep disorders - p. 525 48. Chapter 33: The evolving concept of multimorbidity and migraine - p. 535 49. Section VII: Future directions - p. 565 50. Chapter 34: Healthcare disparities encountered by patients with headache disorders and potential mitigation strategies - p. 569 51. Chapter 35: Emerging and future directions of migraine research and treatment - p. 587 52. Index - p. 597
Migraine Management, Volume 199 covers the effective treatment of migraines, including different subtypes of migraines in different patient populations. The classification and diagnostic criteria of common and uncommon subtypes of migraine is explored in detail, including childhood variants. An in-depth analysis of the pharmacology of acute and prophylactic agents is presented, along with an evidence-based review of pharmacologic management. This includes recently developed CGRP monoclonal antibodies and non-peptide small molecule CGRP antagonists. Advances in neuromodulatory treatments, both noninvasive and implantable, are also critically reviewed.
Finally, specific treatment-related issues in pregnancy and lactation and childhood as well as the elderly are covered. Issues related to the diagnosis and management of vestibular migraine and the co-morbid disorder of persistent postural-perceptual dizziness is also explored.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Series Page - p. iii 5. Copyright - p. iii 6. Handbook of Clinical Neurology 3rd Series - p. iii 7. Foreword - p. ix 8. Preface - p. x 9. Contributors - p. x 10. Section I: Migraine management - p. x 11. Chapter 1: Nonspecific analgesics, combination analgesics, and antiemetics - p. 3 12. Chapter 2: The 5-HT1B and 5-HT1D agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans - p. 17 13. Chapter 3: 5-HT1F agonists - p. 43 14. Chapter 4: CGRP receptor antagonists (gepants) - p. 51 15. Chapter 5: Preventive treatment of migraine: Non-specific oral agents - p. 80 16. Chapter 6: OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment - p. 87 17. Chapter 7: CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention - p. 107 18. Chapter 8: Nutraceuticals in migraine - p. 125 19. Chapter 9: Interventional treatments - p. 145 20. Chapter 10: Biobehavioral treatments of migraine - p. 155 21. Chapter 11: Physical treatment of migraine - p. 171 22. Chapter 12: Neuromodulation in migraine - p. 179 23. Section II: Guidelines - p. 200 24. Chapter 13: Evidence-based symptomatic treatment of migraine - p. 203 25. Chapter 14: Evidence-based preventive treatment of migraine☆ - p. 219 26. Section III: Special cases/situations - p. 241 27. Chapter 15: Treatment in the emergency department - p. 245 28. Chapter 16: Special considerations in migraine during pregnancy and lactation - p. 257 29. Chapter 17: Special considerations in management of migraine in the elderly - p. 265 30. Chapter 18: Management of medication overuse headache - p. 277 31. Section IV: Outcome measures - p. 298 32. Chapter 19: Outcome measures for migraine: Measuring the impact of migraine and results of migraine treatment - p. 316 33. Section V: Diagnosis and treatment of other migraine subtypes - p. 328 34. Chapter 20: Menstrually associated migraine - p. 331 35. Chapter 21: Hemiplegic migraine - p. 353 36. Chapter 22: Migraine with brainstem aura - p. 367 37. Chapter 23: Retinal migraine - p. 381 38. Chapter 24: Vestibular migraine and persistent postural perceptual dizziness - p. 389 39. Chapter 25: Status migrainosus - p. 422 40. Chapter 26: Persistent aura, visual snow, and other visual symptoms - p. 441 41. Chapter 27: Migrainous infarction - p. 465 42. Chapter 28: Migraine in children and adolescents: Assessment and diagnosis - p. 475 43. Chapter 29: Management of migraine in children and adolescents - p. 487 44. Section VI: Comorbidities of migraine - p. 502 45. Chapter 30: Psychiatric comorbidities of migraine - p. 505 46. Chapter 31: Relationship of migraine and other forms of chronic pain - p. 517 47. Chapter 32: Comorbidities of migraine: Sleep disorders - p. 525 48. Chapter 33: The evolving concept of multimorbidity and migraine - p. 535 49. Section VII: Future directions - p. 565 50. Chapter 34: Healthcare disparities encountered by patients with headache disorders and potential mitigation strategies - p. 569 51. Chapter 35: Emerging and future directions of migraine research and treatment - p. 587 52. Index - p. 597
